| EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection P Lampertico, K Agarwal, T Berg, M Buti, HLA Janssen, ... Journal of hepatology 67 (2), 370-398, 2017 | 4624 | 2017 |
| EASL Clinical Practice Guidelines: management of chronic hepatitis B European Association For The Study Of The Liver J Hepatol 50, 227-242, 2009 | 1916 | 2009 |
| Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre–and post–liver transplantation patients ER Schiff, CL Lai, S Hadziyannis, P Neuhaus, N Terrault, M Colombo, ... Hepatology 38 (6), 1419-1427, 2003 | 575 | 2003 |
| Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy: a systematic review GV Papatheodoridis, P Lampertico, S Manolakopoulos, A Lok Journal of hepatology 53 (2), 348-356, 2010 | 539 | 2010 |
| Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage C Dunn, M Brunetto, G Reynolds, T Christophides, PT Kennedy, ... The Journal of Experimental Medicine 204 (3), 667-680, 2007 | 525 | 2007 |
| Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy GV Papatheodoridis, HLY Chan, BE Hansen, HLA Janssen, P Lampertico Journal of hepatology 62 (4), 956-967, 2015 | 515 | 2015 |
| PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 64 (4), 800-806, 2016 | 441 | 2016 |
| Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients P Lampertico, M Vigano, E Manenti, M Iavarone, E Sablon, M Colombo Gastroenterology 133 (5), 1445-1451, 2007 | 440 | 2007 |
| Restored Function of HBV-Specific T Cells after Long-Term Effective Therapy with Nucleos (t) ide Analogues C Boni, D Laccabue, P Lampertico, T Giuberti, M Viganò, S Schivazappa, ... Gastroenterology Jul 14. [Epub ahead of print], 2012 | 399 | 2012 |
| Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine P Lampertico, M Viganò, E Manenti, M Iavarone, G Lunghi, M Colombo Hepatology 42 (6), 1414-1419, 2005 | 375 | 2005 |
| Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine V Di Marco, A Marzano, P Lampertico, P Andreone, T Santantonio, ... Hepatology 40 (4), 883-891, 2004 | 362* | 2004 |
| Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results E Schiff, CL Lai, S Hadziyannis, P Neuhaus, N Terrault, M Colombo, ... Liver Transplantation 13 (3), 349-360, 2007 | 344 | 2007 |
| Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients WR Kim, T Berg, T Asselah, R Flisiak, S Fung, SC Gordon, HLA Janssen, ... Journal of hepatology 64 (4), 773-780, 2016 | 334 | 2016 |
| Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B P Fisicaro, V Barili, B Montanini, G Acerbi, M Ferracin, F Guerrieri, ... Nature medicine 23 (3), 327-336, 2017 | 314 | 2017 |
| Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy P Lampertico, E Del Ninno, M Viganò, R Romeo, MF Donato, E Sablon, ... Hepatology 37 (4), 756-763, 2003 | 305 | 2003 |
| Prophylaxis and treatment of hepatitis B in immunocompromised patients A Marzano, E Angelucci, P Andreone, M Brunetto, R Bruno, P Burra, ... Digestive and Liver Disease 39 (5), 397-408, 2007 | 284 | 2007 |
| A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum P Lampertico, E Del Ninno, A Manzin, MF Donato, MG Rumi, G Lunghi, ... Hepatology 26 (6), 1621-1625, 1997 | 267 | 1997 |
| Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients G Raimondo, MR Brunetto, P Pontisso, A Smedile, AM Maina, C Saitta, ... Hepatology 43 (1), 100-107, 2006 | 261 | 2006 |
| Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a V Rijckborst, BE Hansen, P Ferenci, MR Brunetto, F Tabak, Y Cakaloglu, ... Journal of Hepatology 56 (5), 1006-11, 2012 | 223 | 2012 |
| Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir GV Papatheodoridis, GN Dalekos, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 62 (2), 363-370, 2015 | 179 | 2015 |
